Chenxiong Le

A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients

Brandon W. Higgs, Wei Zhu, Chris Morehouse et al. · Annals of the Rheumatic Diseases · 2013 · 166 citations · Full text

Life Sciences, Immunology, Pharmacology +13

Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma

Joseph M. Parker, Chad K. Oh, Craig LaForce et al. · BMC Pulmonary Medicine · 2011 · 143 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Age‐conditional probabilities of developing cancer

Michael P. Fay, Ruth M. Pfeiffer, Kathleen A. Cronin et al. · Statistics in Medicine · 2003 · 106 citations · Full text

Medicine, Biostatistics, Oncology +17

Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial

John F. Kokai‐Kun, Tracey Roberts, Olivia Coughlin et al. · The Lancet Infectious Diseases · 2019 · 84 citations

Medicine, Infectious Diseases, Pharmacology +16

A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti–interferon-alfa monoclonal antibody, in subjects with chronic psoriasis

Robert Bissonnette, Kim Papp, Catherine Maari et al. · Journal of the American Academy of Dermatology · 2010 · 80 citations

Life Sciences, Immunology, Pharmacotherapy +12